CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nutriband Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nutriband Inc
121 S Orange Ave Ste 1500
Phone: (407) 377-6695p:407 377-6695 ORLANDO, FL  32801-3241  United States Ticker: NTRBNTRB
Business Summary
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
7/31/20241/31/2024YesYes---

Industries
SIC Code Description
3842 Orthopedic, prosthetic, and surgical appliances and supplies
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Secretary SergueiMelnik 50 1/21/2022 1/1/2016
Chief Executive Officer and Director GarethSheridan
Chief Financial Officer and Director SergueiMelnik
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
4P Therapeutics Inc. 480 Engineering Drive Peachtree Corners GA United States

Business Names
Business Name
4P Therapeutics Inc.
4P Therapeutics LLC
NTRB
NTRBD
Pocono Pharmaceuticals Inc.

General Information
Number of Employees: 13 (As of 1/31/2022)
Outstanding Shares: 11,096,185 (As of 9/3/2024)
Shareholders: 110
Stock Exchange: NASD
Federal Tax Id: 811118176


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024